Form 4: Cytokinetics EVP Andrew Callos Reports Stock Option Exercise and Sale

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, exercised stock options and sold a portion of the acquired shares on March 14, 2025.

Summary

• On March 14, 2025, Andrew Callos, the EVP and Chief Commercial Officer of Cytokinetics Inc., exercised non-qualified stock options to acquire 100 shares of common stock at a price of $23.26 per share.
• Simultaneously, Mr. Callos sold 100 shares of common stock at a price of $45 per share.
• Following these transactions, Mr. Callos directly owns 37,663 shares of Cytokinetics Inc.
• Mr. Callos also holds options to purchase 149,900 shares of common stock.

Sentiment

Score: 5

Explanation: This is a neutral report of insider trading activity, with no inherent positive or negative implications for the company's overall prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. It's common for executives to exercise stock options and sell a portion of the shares for personal financial management.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it involves a small number of shares.
• The disclosure provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates